AI Article Synopsis
- The study aimed to explore how genetic variations in the ABCB1 and CYP2D6 genes affect how the body processes risperidone, a medication used for psychiatric conditions.
- A group of 72 healthy Korean participants took a single dose of risperidone, showing significant differences in blood levels of the drug based on their ABCB1 gene variations.
- The results suggest that certain genetic profiles, especially ABCB1 3435C>T in individuals with low CYP2D6 activity, may influence the risk of adverse effects from risperidone.
Article Abstract
Background And Purpose: The objective of this study was to investigate the combined influence of genetic polymorphisms in ABCB1 and CYP2D6 genes on risperidone pharmacokinetics.
Experimental Approach: Seventy-two healthy Korean volunteers receiving a single oral dose of 2 mg risperidone were included in this study.
Key Results: Significant differences were observed between the ABCB1 3435C>T genotypes for the pharmacokinetic parameters (peak serum concentration) of risperidone and the active moiety (risperidone and its main metabolite, 9-hydroxyrisperidone). There were no significant differences in the area under the serum concentration-time curves of risperidone and the active moiety among the ABCB1 2677G>T/A and 3435C>T genotypes. However, the peak serum concentration and area under the serum concentration-time curves were significantly different among the ABCB1 3435C>T genotypes in CYP2D6*10/*10.
Conclusions And Implications: These findings indicate that polymorphisms of ABCB1 3435C>T in individuals with CYP2D6*10/*10, which has low metabolic activity, could play an important role in the potential adverse effects or toxicity of risperidone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188890 | PMC |
| http://dx.doi.org/10.1111/j.1476-5381.2011.01385.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polymorphism Is Associated with Higher Carbamazepine Clearance in Children.
Pediatr Rep
January 2025
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34 000 Kragujevac, Serbia.
The aim of our study was to investigate the role of polymorphism in the pharmacokinetics of carbamazepine (CBZ) in children. The study enrolled 47 Serbian pediatric epileptic patients on CBZ treatment. Genotyping for 1236C
Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study.
Pharmacogenomics
January 2025
Department of Clinical Pharmacology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
Background: Macrolides are widely used antibiotics, but adverse drug reactions (ADRs), particularly in genetically predisposed individuals, can compromise their safety. This study examines the impact of pharmacogenetic markers on macrolide safety in participants with bacterial complications of influenza.
Objective: To evaluate how polymorphisms in genes encoding transporter proteins (ABCB1) and enzymes (CYP3A4, CYP3A5) influence ADR risk during macrolide therapy.
Personalization of clopidogrel therapy based on genetic polymorphism analysis: clinical implications.
Am J Transl Res
October 2024
Department of Pharmacy, Wuhu Hospital Affiliated to East China Normal University Wuhu 241000, Anhui, China.
Objective: This study aimed to evaluate the impact of gene polymorphisms on clopidogrel metabolism and to use this analysis to inform treatment strategy for a population in southern Anhui of China.
Methods: The research was conducted from 2019 to 2022, aincluding 430 patients from the Wuhu Hospital, affiliated with East China Normal University who were candidates for clopidogrel therapy. Genes influencing clopidogrel's absorption and metabolism were analyzed to guide treatment.
Association Between -24C>T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer.
Anticancer Res
November 2024
Department of Cancer Genome and Pharmacotherapy, Showa University Graduate School of Pharmacy, Tokyo, Japan;
Background/aim: Nab-paclitaxel is used to treat patients with pancreatic cancer. However, it frequently induces peripheral neuropathy. Notably, pharmacokinetic factors may be associated with neuropathic symptoms as the onset depends on the cumulative dose.
View Article and Find Full Text PDFAnalysis of ABCB1 Gene Polymorphisms and Their Impact on Tacrolimus Blood Levels in Kidney Transplant Recipients.
Int J Mol Sci
October 2024
Department of Immunology and Transplant Immunology, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.
Tacrolimus (Tc) is an immunosuppressant used in transplant patients, but its therapeutic range is narrow, making precise dosing essential. This study investigates the association of three single nucleotide polymorphisms (SNPs) (ABCB1 3435C>T, 1236C>T, 2677G>T/A) with Tc levels over time to gain better insights into their role in personalized medicine. We conducted the study over four distinct periods: 1-14 days, 15-30 days, 31-60 days, and beyond 60 days post-transplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!